TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15690650

Group type: EXPERIMENTAL
Intervention: Retinol palmitate (10,000 IU by mouth for 90 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Retinol palmitate (after crossover from placebo)
Number of subjects: 19
Study: 12088517

Group type: EXPERIMENTAL
Intervention: Inulin+oligofructose mixture
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Oligofructose
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo (sucrose)
Number of subjects: 59
Study: 9530125

Group type: EXPERIMENTAL
Intervention: daily exercise program (55% peak oxygen uptake)
Number of subjects: 19

Group type: COMPARATOR
Intervention: sedentary life
Number of subjects: 19
Study: 8556776

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (25-50 mg daily for at least six months)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (500 mg daily for 30 days)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Magnesium chloride supplementation (1 g daily for 30 days)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (unmedicated normotensive men)
Number of subjects: 39
Study: 2532922

Group type: EXPERIMENTAL
Intervention: Fenoterol hydrobromide (800 micrograms)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (80 micrograms)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo (propellant only)
Number of subjects: 79
Study: 323705

Group type: EXPERIMENTAL
Intervention: 2.5 mg of estrogen
Number of subjects: 2680

Group type: EXPERIMENTAL
Intervention: 5.0 mg of estrogen
Number of subjects: 2680

Group type: EXPERIMENTAL
Intervention: 1.8 g of clofibrate
Number of subjects: 2680

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2680
Study: 31724878

Group type: EXPERIMENTAL
Intervention: isCGM (intermittently scanned continuous glucose monitoring)
Number of subjects: 59

Group type: COMPARATOR
Intervention: SMBG (self‐monitoring of blood glucose)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: isCGM
Number of subjects: 59
Study: 28871620

Group type: EXPERIMENTAL
Intervention: Oropharyngeal surfactant (1.5 mL of Curosurf) with sustained inflation manoeuvre (SIM)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (20 infants born before the study period)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (20 infants born after the study period)
Number of subjects: 19
Study: 27919362

Group type: EXPERIMENTAL
Intervention: OM3‐CA (omega‐3 carboxylic acids) 2, 3, or 4 g/d
Number of subjects: 399

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 399
Study: 24534599

Group type: EXPERIMENTAL
Intervention: Optimal medical therapy goals (aspirin use, blood pressure control, cholesterol levels, glucose levels, nonsmoking status, body mass index, exercise frequency)
Number of subjects: 3167
Study: 22100903

Group type: EXPERIMENTAL
Intervention: BMI (per 5 kg/m(2) increase) for type 1 carcinomas
Number of subjects: 1070

Group type: EXPERIMENTAL
Intervention: BMI (per 5 kg/m(2) increase) for type 2 carcinomas
Number of subjects: 1070
Study: 20868963

Group type: EXPERIMENTAL
Intervention: Group PE (priming + ephedrine)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Group P (priming)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Group E (ephedrine)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Group NPE (no priming, no ephedrine)
Number of subjects: 124
Study: 18378290

Group type: EXPERIMENTAL
Intervention: Implementation intentions (specific action plans for sunscreen use)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Questionnaire-only control group
Number of subjects: 436
Study: 15893104

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral relapse prevention support group (RPSG)
Number of subjects: 291

Group type: EXPERIMENTAL
Intervention: Individualized assessment and advice group (IAI)
Number of subjects: 291

Group type: COMPARATOR
Intervention: Delayed treatment control group (DTC)
Number of subjects: 291
Study: 12124484

Group type: EXPERIMENTAL
Intervention: Regional cerebral blood flow (rCBF) measured by SPECT using the N‐isopropyl‐p‐[(123)I]iodoamphetamine autoradiography method
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Regional cerebral blood flow (rCBF) measured by SPECT
Number of subjects: 59
Study: 9650874

Group type: EXPERIMENTAL
Intervention: Scaling with systemic metronidazole plus amoxicillin and supragingival irrigation with chlorhexidine digluconate
Number of subjects: 48

Group type: COMPARATOR
Intervention: Full‐mouth scaling alone
Number of subjects: 48
Study: 7662221

Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (12.5 mg/day)
Number of subjects: 28
Study: 2527541

Group type: EXPERIMENTAL
Intervention: Nitrendipine 10 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Cilazapril 1.25 or 2.5 mg
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nitrendipine and Cilazapril combined
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 824468

Group type: EXPERIMENTAL
Intervention: Low-dose penicillin (procaine penicillin G, 600,000 units intramuscularly, every 12 hours for up to ten days)
Number of subjects: 63

Group type: COMPARATOR
Intervention: High-dose penicillin (procaine penicillin G, same regimen as low-dose plus intravenous aqueous penicillin G, 10 million units daily for the first three days)
Number of subjects: 63

Group type: COMPARATOR
Intervention: High-dose penicillin
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Low-dose penicillin
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Low-dose penicillin and high-dose penicillin
Number of subjects: 63
Study: 30706519

Group type: EXPERIMENTAL
Intervention: Mentors with visual impairment (VI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mentors without visual impairment (VI)
Number of subjects: 0
Study: 28612547

Group type: EXPERIMENTAL
Intervention: rTMS + SC
Number of subjects: 33

Group type: COMPARATOR
Intervention: rTMS
Number of subjects: 33
Study: 26424428

Group type: EXPERIMENTAL
Intervention: Cranial electrical stimulation (CES) at 15/500/15,000 Hz, symmetrical rectangular biphasic current of 1-4 mAmp, 40 V for 20 min, 5 days per week for 3 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham CES (device off) for 20 min, 5 days per week for 3 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cranial electrical stimulation (CES)
Number of subjects: 30
Study: 23401601

Group type: EXPERIMENTAL
Intervention: 100 mg loading dose of leflunomide (LEF) for 3 days, followed by 20 mg LEF daily for 3 months
Number of subjects: 120

Group type: COMPARATOR
Intervention: 20 mg fixed dose of leflunomide (LEF) for 3 days, followed by 20 mg LEF daily for 3 months
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups (loading-dose and fixed-dose)
Number of subjects: 120
Study: 21475137

Group type: EXPERIMENTAL
Intervention: Low-calorie diet with carbohydrates eaten mostly at dinner
Number of subjects: 78
Study: 19419359

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (SA) with bupivacaine 15 mg, 0.15 mg of intrathecal morphine and 15 microg of fentanyl
Number of subjects: 40

Group type: COMPARATOR
Intervention: General anesthesia (GA) with sufentanil
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (SA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 40
Study: 17724395

Group type: EXPERIMENTAL
Intervention: Exercise training with weighted vests (3 sessions per week for 12 weeks, vest load up to 15% of body weight)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Exercise training with weighted vests
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 16
Study: 14998850

Group type: EXPERIMENTAL
Intervention: Oxaliplatin alone (OXA)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Oxaliplatin combined with infusional 5-FU (OXFU)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Infusional 5-FU alone (5-FU)
Number of subjects: 63
Study: 11800513

Group type: EXPERIMENTAL
Intervention: Experimental interventions (theory of gender and power, social learning theory, cognitive behavioral theory)
Number of subjects: 445

Group type: COMPARATOR
Intervention: Waiting list control condition
Number of subjects: 445

Group type: EXPERIMENTAL
Intervention: Experimental interventions
Number of subjects: 445
Study: 9555617

Group type: EXPERIMENTAL
Intervention: Salbutamol + Ipratropium (100 micrograms/inh salbutamol + 20 micrograms/inh ipratropium)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Salbutamol (100 micrograms/inh)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Ipratropium (20 micrograms/inh)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Salbutamol + Ipratropium
Number of subjects: 120
Study: 7981560

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg/day)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 30442080

Group type: EXPERIMENTAL
Intervention: Trandolapril (ACE inhibitor)
Number of subjects: 2512
Study: 26363481

Group type: EXPERIMENTAL
Intervention: Transvaginal cervical length (TVCL) assessment and digital exams monthly from 16‐28 weeks with standard management algorithm for activity restriction and cerclage
Number of subjects: 125

Group type: COMPARATOR
Intervention: Monthly digital cervical examinations without routine TVCL ultrasound
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Transvaginal cervical length (TVCL) assessment
Number of subjects: 125

Group type: COMPARATOR
Intervention: Control group (no routine TVCL)
Number of subjects: 125
Study: 24892203

Group type: EXPERIMENTAL
Intervention: Audio tempo at 125% of baseline cadence
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Audio tempo at 75% and 100% of baseline cadence
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Optic flow (50% and 100% of preferred walking speed)
Number of subjects: 36
Study: 22193628

Group type: EXPERIMENTAL
Intervention: Novel conditionally replicating adenoviral vector (CRAd) expressing IL-24 and arresten
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 18332150

Group type: EXPERIMENTAL
Intervention: Culturally appropriate stroke education program, divided into four 50-minute classes each year during sixth, seventh, and eighth grades.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study: 19738135

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 27111

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS) after multivariable adjustment
Number of subjects: 27111

Group type: EXPERIMENTAL
Intervention: Each additional MetS-defining trait
Number of subjects: 27111

Group type: COMPARATOR
Intervention: High-sensitivity C-reactive protein
Number of subjects: 27111

Group type: COMPARATOR
Intervention: Soluble intercellular adhesion molecule-1
Number of subjects: 27111

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS) with inflammation markers included in multivariable models
Number of subjects: 27111
Study: 16859225

Group type: EXPERIMENTAL
Intervention: Sterile saline
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Acetic acid
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Neomycin-polymyxin solution
Number of subjects: 89
Study: 12590375

Group type: EXPERIMENTAL
Intervention: Clonidine 0.15 mg/day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 10867600

Group type: EXPERIMENTAL
Intervention: Respimat delivering 50/20, 25/20 or 25/10 microg F/I per puff
Number of subjects: 43

Group type: COMPARATOR
Intervention: MDI delivering 50/20 microg F/I per puff
Number of subjects: 43
Study: 9355894

Group type: EXPERIMENTAL
Intervention: Mibefradil 100 mg
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Mibefradil 150 mg
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 309
Study: 8408529

Group type: EXPERIMENTAL
Intervention: RU486 (600 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RU486 (3 x 25 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RU486 (25 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2880597

Group type: EXPERIMENTAL
Intervention: Low alcohol content beer only
Number of subjects: 46
Study: 29995949

Group type: EXPERIMENTAL
Intervention: Exclusively breastfed until age 4‐5 months
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Exclusively breastfed until age 6‐10 months
Number of subjects: 236

Group type: COMPARATOR
Intervention: Exclusively breastfed for 0‐1 months
Number of subjects: 236
Study: 27325848

Group type: EXPERIMENTAL
Intervention: Telephone genetic counseling
Number of subjects: 988
Study: 25046068

Group type: EXPERIMENTAL
Intervention: Nasal packing and transseptal suture technique (Group 1, n=16)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Transseptal suture technique (Group 2, n=22)
Number of subjects: 38
Study: 22469880

Group type: EXPERIMENTAL
Intervention: Combined exercise program (6 months)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 41
Study: 20439295

Group type: EXPERIMENTAL
Intervention: Rituximab plus methotrexate (MTX)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX)
Number of subjects: 468
Study: 18633045

Group type: EXPERIMENTAL
Intervention: CEA regional
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (sedation)
Number of subjects: 60
Study: 15722780

Group type: EXPERIMENTAL
Intervention: Drug therapies for complex regional pain syndrome
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy coupled with functional restoration and interdisciplinary approach
Number of subjects: 0
Study: 12229131

Group type: COMPARATOR
Intervention: Morphine (IV PCA) alone (2 mg bolus, 10-minute lock-out interval, 10 mg/hour limit for 48 hours)
Number of subjects: 20
Study: 10102019

Group type: EXPERIMENTAL
Intervention: Conventional cranial irradiation (CRT) regimen (L874A and I874A) - 18-Gy CRT plus 3 doses of intrathecal (i.t.) MTX
Number of subjects: 572

Group type: COMPARATOR
Intervention: High-dose methotrexate (HDMTX) regimen without CRT (L874B and I874B) - 3 courses of HDMTX at 2 g/m2 plus 13 doses of ITMTX or 4 courses of HDMTX at 4.5 g/m2 plus 1 dose of ITMTX
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Conventional cranial irradiation (CRT) regimen (I874A)
Number of subjects: 572

Group type: COMPARATOR
Intervention: High-dose methotrexate (HDMTX) regimen without CRT (I874B)
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Intensive systemic chemotherapy with extended i.t. injections of MTX plus cytarabine
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Cranial irradiation (18-Gy or 24-Gy) with intensive systemic chemotherapy
Number of subjects: 572
Study: 7770400

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg)
Number of subjects: 545

Group type: COMPARATOR
Intervention: Ranitidine (300 mg)
Number of subjects: 545
Study: 2265371

Group type: EXPERIMENTAL
Intervention: HPP 3 x 300 mg po, days 1-5, 5-FU 800 mg/m2 push iv, days 3-5 and DDP 50 mg/m2 d6
Number of subjects: 104

Group type: COMPARATOR
Intervention: 5-FU alone 500 mg/m2 push iv days 1-5
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: HPP-5-FU-DDP
Number of subjects: 104

Group type: COMPARATOR
Intervention: 5-FU
Number of subjects: 104
Study: 7004247

Group type: EXPERIMENTAL
Intervention: Oxatomide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Cinnarizine in combination with phenylpropanolamine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 31567951

Group type: EXPERIMENTAL
Intervention: PNF-treated group (respiratory stimulation through Proprioceptive Neuromuscular Facilitation)
Number of subjects: 60

Group type: COMPARATOR
Intervention: PNF-untreated group (positioning)
Number of subjects: 60
Study: 28248418

Group type: EXPERIMENTAL
Intervention: Customized behavioral urinary incontinence treatments combined with physical activity (150 minutes of weekly walking and twice weekly strength training classes)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Customized behavioral urinary incontinence treatments combined with physical activity
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 42
Study: 25271779

Group type: EXPERIMENTAL
Intervention: Group cognitive-behavioral therapy (22 sessions)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Group supportive therapy (control, 22 sessions)
Number of subjects: 44
Study: 23357523

Group type: EXPERIMENTAL
Intervention: General anaesthesia plus epidural (GAE)
Number of subjects: 226
Study: 21733037

Group type: EXPERIMENTAL
Intervention: Aerobic exercise at an intensity of 50‐65% of maximum heart rate for 60 min, three times a week for 16 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual physical activity
Number of subjects: 64
Study: 19731229

Group type: EXPERIMENTAL
Intervention: Seldinger technique
Number of subjects: 152

Group type: COMPARATOR
Intervention: venous cutdown
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: both techniques
Number of subjects: 152
Study: 17596103

Group type: EXPERIMENTAL
Intervention: Vildagliptin 25 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Vildagliptin 10 mg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Vildagliptin 25 mg and 100 mg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 14872477

Group type: EXPERIMENTAL
Intervention: Escalating doses of IM methotrexate up to 45 mg/week
Number of subjects: 64

Group type: COMPARATOR
Intervention: 15 mg/week IM methotrexate with monthly placebo escalation
Number of subjects: 64
Study: 11163032

Group type: EXPERIMENTAL
Intervention: Allopurinol (administered with pre-medication)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Standard care (without allopurinol)
Number of subjects: 29
Study: 9250753

Group type: EXPERIMENTAL
Intervention: Reinfusion of unwashed blood salvaged after operation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Homologous bank blood
Number of subjects: 70
Study: 7684865

Group type: EXPERIMENTAL
Intervention: Strontium-89 (400 MBq)
Number of subjects: 126
Study: 3430248

Group type: COMPARATOR
Intervention: WHO ORS
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Pop rice ORS
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Mung bean ORS
Number of subjects: 93
Study: 31180297

Group type: EXPERIMENTAL
Intervention: Epoetin beta treatment to a hemoglobin target level of 11.5 to 13.5 g/dL
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Epoetin beta treatment
Number of subjects: 55

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 55
Study: 30026086

Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Neurally Adjusted Ventilatory Assist (NAVA)
Number of subjects: 8
Study: 28069598

Group type: EXPERIMENTAL
Intervention: Interactive Voice Response brief intervention (IVR‐BI)
Number of subjects: 1855

Group type: COMPARATOR
Intervention: No IVR‐BI control
Number of subjects: 1855

Group type: EXPERIMENTAL
Intervention: Both conditions (IVR‐BI and No IVR‐BI)
Number of subjects: 1855
Study: 25446490

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy (SILC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (LC)
Number of subjects: 100
Study: 22684155

Group type: EXPERIMENTAL
Intervention: Blended learning group (additional online access to the PENSKE Baby Check Learning Module)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (standard neonatology teaching programme)
Number of subjects: 81
Study: 22070129

Group type: EXPERIMENTAL
Intervention: P‐R drink (n = 20)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo (n = 19)
Number of subjects: 39
Study: 19523092

Group type: EXPERIMENTAL
Intervention: Intra-observer measurement
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Inter-observer measurement
Number of subjects: 70
Study: 16681436

Group type: EXPERIMENTAL
Intervention: Adrenocorticotrophic hormone (ACTH)(1‐24) 1 mg i.m. daily for 4 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cortisol 50 mg i.m. t.i.d. for 4 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (observed for 4 days)
Number of subjects: 30
Study: 15530678

Group type: EXPERIMENTAL
Intervention: dTpa
Number of subjects: 0

Group type: COMPARATOR
Intervention: DTPa
Number of subjects: 0
Study: 11177066

Group type: EXPERIMENTAL
Intervention: Individualized safer sex intervention (videotape and intervention session)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Standard STD education (control)
Number of subjects: 123
Study: 9771317

Group type: EXPERIMENTAL
Intervention: Extubation while awake
Number of subjects: 84

Group type: COMPARATOR
Intervention: Extubation while sedated (propofol 1‐3 mg kg‐1 h‐1)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Extubation while sedated
Number of subjects: 84
Study: 7827234

Group type: EXPERIMENTAL
Intervention: 1-step procedure for fixture installation and abutment connection
Number of subjects: 11

Group type: COMPARATOR
Intervention: 2-step procedure for fixture installation and abutment connection
Number of subjects: 11
Study: 3063797

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg sublingually
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nifedipine 10 mg sublingually
Number of subjects: 22
Study: 30958836

Group type: EXPERIMENTAL
Intervention: Video-based Apple Keynote presentation
Number of subjects: 45

Group type: COMPARATOR
Intervention: Serious game in a 3D learning environment
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Serious game
Number of subjects: 45
Study: 28981820

Group type: EXPERIMENTAL
Intervention: 8% cooked starch
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 8% raw starch
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Salivary α-amylase activity
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Effective α-amylase activity
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Carbohydrate consumption score
Number of subjects: 5
Study: 25349295

Group type: EXPERIMENTAL
Intervention: FOLFOX (infusional fluorouracil, leucovorin, and oxaliplatin)
Number of subjects: 1002
Study: 24138652

Group type: EXPERIMENTAL
Intervention: CTCA followed by CCA
Number of subjects: 0

Group type: COMPARATOR
Intervention: CCA alone
Number of subjects: 0